Mastocytosis and hymenopteran poison allergy profiled in the US


The prevalence of hymenopteran poison anaphylaxis (HVA) in the United States is 0.167% and mastocytosis is more common among those with HVA, according to a study recently published in Journal of Allergy and Clinical Immunology.

Charles F. Schuler, IV, MD, of the University of Michigan at Ann Arbor, and colleagues used insurance claims data from approximately 27 million U.S. patients in 2018 to examine the prevalence of ‘HVA and mastocytosis in the United States and evaluated the impact of mastocytosis. turned on immunotherapy (VIT) in a cohort of American patients with HVA.

The researchers found that the prevalence of HVA was 167 per 100,000 (0.167 percent) and the prevalence of mastocytosis was 10 per 100,000 overall and 97 per 100,000 with HVA (0.010 and 0.097 percent, respectively). In a cohort of 161 patients undergoing VIT between 2015 and 2018, 2.6 percent had mastocytosis. There was no correlation for tryptase level with the severity of the poison reaction, but the level was higher in patients with systemic VIT reactions.

“Mastocytosis may be less common in the American population compared to European reports of systemic poison reactions, but there remains a strong association between HVA and mastocytosis,” the authors write.

One author revealed links to Healgen Scientific and Access Bio Inc.

Bone marrow disorder almost ten times more common in people with poison allergy

More information:
Summary / Full text (subscription or payment may be required)

© 2021 HealthDay. All rights reserved.

Citation: Allergy to Mastocytosis and Hymenoptera Poison Allergy Profiled in the United States (2021, June 3) Retrieved June 3, 2021 at -profiled.html

This document is subject to copyright. Apart from any fair treatment for private study or research purposes, no part may be reproduced without written permission. Content is provided for informational purposes only.

Source link